These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1431591)

  • 1. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III.
    McConathy WJ; Gesquiere JC; Bass H; Tartar A; Fruchart JC; Wang CS
    J Lipid Res; 1992 Jul; 33(7):995-1003. PubMed ID: 1431591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.
    Wang CS; McConathy WJ; Kloer HU; Alaupovic P
    J Clin Invest; 1985 Feb; 75(2):384-90. PubMed ID: 3973011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein lipase-catalyzed hydrolysis of phosphatidylcholine of guinea pig very low density lipoproteins and discoidal complexes of phospholipid and apolipoprotein: effect of apolipoprotein C-II on the catalytic mechanism.
    Shirai K; Fitzharris TJ; Shinomiya M; Muntz HG; Harmony JA; Jackson RL; Quinn DM
    J Lipid Res; 1983 Jun; 24(6):721-30. PubMed ID: 6688442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins.
    Tornoci L; Scheraldi CA; Li X; Ide H; Goldberg IJ; Le NA
    J Lipid Res; 1993 Oct; 34(10):1793-803. PubMed ID: 8245727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV.
    Goldberg IJ; Scheraldi CA; Yacoub LK; Saxena U; Bisgaier CL
    J Biol Chem; 1990 Mar; 265(8):4266-72. PubMed ID: 2307668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a lipoprotein lipase cofactor-binding site by chemical cross-linking and transfer of apolipoprotein C-II-responsive lipolysis from lipoprotein lipase to hepatic lipase.
    McIlhargey TL; Yang Y; Wong H; Hill JS
    J Biol Chem; 2003 Jun; 278(25):23027-35. PubMed ID: 12682050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the apolipoprotein C-II/C-III1 ratio on the capacity of purified milk lipoprotein lipase to hydrolyse triglycerides in monolayer vesicles.
    Lambert DA; Catapano AL; Smith LC; Sparrow JT; Gotto AM
    Atherosclerosis; 1996 Dec; 127(2):205-12. PubMed ID: 9125310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets.
    Larsson M; Vorrsjö E; Talmud P; Lookene A; Olivecrona G
    J Biol Chem; 2013 Nov; 288(47):33997-34008. PubMed ID: 24121499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III.
    Sun HY; Lin CC; Lee JC; Wang SW; Cheng PN; Wu IC; Chang TT; Lai MD; Shieh DB; Young KC
    Gut; 2013 Aug; 62(8):1193-203. PubMed ID: 22689516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inverse association between apolipoprotein C-II and cardiovascular mortality: role of lipoprotein lipase activity modulation.
    Silbernagel G; Chen YQ; Rief M; Kleber ME; Hoffmann MM; Stojakovic T; Stang A; Sarzynski MA; Bouchard C; März W; Qian YW; Scharnagl H; Konrad RJ
    Eur Heart J; 2023 Jul; 44(25):2335-2345. PubMed ID: 37155355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of recombinant wild type and site-directed mutations of apolipoprotein C-III: lipid binding, displacement of ApoE, and inhibition of lipoprotein lipase.
    Liu H; Talmud PJ; Lins L; Brasseur R; Olivecrona G; Peelman F; Vandekerckhove J; Rosseneu M; Labeur C
    Biochemistry; 2000 Aug; 39(31):9201-12. PubMed ID: 10924113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein C-II39-62 activates lipoprotein lipase by direct lipid-independent binding.
    MacPhee CE; Hatters DM; Sawyer WH; Howlett GJ
    Biochemistry; 2000 Mar; 39(12):3433-40. PubMed ID: 10727238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of lipoprotein lipase by native and synthetic fragments of human plasma apolipoprotein C-II.
    Kinnunen PK; Jackson RL; Smith LC; Gotto AM; Sparrow JT
    Proc Natl Acad Sci U S A; 1977 Nov; 74(11):4848-51. PubMed ID: 270715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr.
    Liu H; Labeur C; Xu CF; Ferrell R; Lins L; Brasseur R; Rosseneu M; Weiss KM; Humphries SE; Talmud PJ
    J Lipid Res; 2000 Nov; 41(11):1760-71. PubMed ID: 11060345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of plasma apolipoproteins on lipoprotein lipase-mediated lipolysis of small and large lipid emulsions.
    Yamamoto M; Morita SY; Kumon M; Kawabe M; Nishitsuji K; Saito H; Vertut-Doï A; Nakano M; Handa T
    Biochim Biophys Acta; 2003 Jun; 1632(1-3):31-9. PubMed ID: 12782148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of lipoprotein lipase by apolipoprotein C-II is modulated by the COOH terminal region of apolipoprotein C-III.
    Catapano AL
    Chem Phys Lipids; 1987 Oct; 45(1):39-47. PubMed ID: 3446410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL.
    Berbée JF; van der Hoogt CC; Sundararaman D; Havekes LM; Rensen PC
    J Lipid Res; 2005 Feb; 46(2):297-306. PubMed ID: 15576844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydrolysis of guinea pig nascent very low density lipoproteins catalyzed by lipoprotein lipase: activation by hjman apolipoprotein C-II.
    Fitzharris TJ; Quinn DM; Goh EH; Johnson JD; Kashyap ML; Srivastava LS; Jackson RL; Harmony JA
    J Lipid Res; 1981 Aug; 22(6):921-33. PubMed ID: 7276752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL.
    Westerterp M; de Haan W; Berbée JF; Havekes LM; Rensen PC
    J Lipid Res; 2006 Jun; 47(6):1203-11. PubMed ID: 16537968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein.
    Weisgraber KH; Mahley RW; Kowal RC; Herz J; Goldstein JL; Brown MS
    J Biol Chem; 1990 Dec; 265(36):22453-9. PubMed ID: 2266137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.